Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 22 | 2025 | 1103 | 4.500 |
Why?
|
| Cardiomyopathies | 6 | 2023 | 508 | 2.000 |
Why?
|
| Acute-On-Chronic Liver Failure | 4 | 2025 | 78 | 1.640 |
Why?
|
| Biliary Atresia | 4 | 2024 | 206 | 1.620 |
Why?
|
| Liver Cirrhosis | 7 | 2024 | 899 | 1.330 |
Why?
|
| Liver Failure, Acute | 4 | 2024 | 94 | 1.200 |
Why?
|
| Bile Acids and Salts | 5 | 2023 | 256 | 1.190 |
Why?
|
| Myocardium | 3 | 2021 | 908 | 1.140 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 191 | 1.000 |
Why?
|
| Multiple Organ Failure | 3 | 2022 | 145 | 0.850 |
Why?
|
| Airway Extubation | 1 | 2024 | 70 | 0.830 |
Why?
|
| Liver | 4 | 2023 | 1816 | 0.770 |
Why?
|
| Renal Replacement Therapy | 3 | 2024 | 155 | 0.680 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 501 | 0.660 |
Why?
|
| Myocardial Contraction | 2 | 2018 | 254 | 0.610 |
Why?
|
| Perioperative Care | 1 | 2021 | 214 | 0.610 |
Why?
|
| Tracheostomy | 1 | 2021 | 201 | 0.600 |
Why?
|
| Cholic Acids | 1 | 2018 | 16 | 0.590 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 55 | 0.570 |
Why?
|
| Critical Care | 2 | 2021 | 687 | 0.570 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2018 | 303 | 0.560 |
Why?
|
| Plasma Exchange | 1 | 2018 | 88 | 0.540 |
Why?
|
| Hemodynamics | 1 | 2021 | 860 | 0.530 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 135 | 0.530 |
Why?
|
| Cholic Acid | 3 | 2014 | 19 | 0.530 |
Why?
|
| Infant | 15 | 2024 | 13195 | 0.510 |
Why?
|
| Child | 23 | 2024 | 25827 | 0.450 |
Why?
|
| Retrospective Studies | 16 | 2024 | 17364 | 0.440 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3139 | 0.420 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 88 | 0.410 |
Why?
|
| Pyridines | 2 | 2014 | 248 | 0.400 |
Why?
|
| Hospital Costs | 2 | 2024 | 180 | 0.400 |
Why?
|
| Cholestasis | 2 | 2014 | 157 | 0.390 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 206 | 0.380 |
Why?
|
| Thrombolytic Therapy | 1 | 2014 | 216 | 0.380 |
Why?
|
| Child, Preschool | 14 | 2024 | 14857 | 0.370 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 189 | 0.360 |
Why?
|
| Waiting Lists | 2 | 2021 | 236 | 0.350 |
Why?
|
| Heart Atria | 1 | 2013 | 333 | 0.340 |
Why?
|
| Male | 25 | 2024 | 65061 | 0.340 |
Why?
|
| Bile Duct Diseases | 1 | 2010 | 17 | 0.330 |
Why?
|
| Anticoagulants | 4 | 2022 | 607 | 0.310 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2010 | 158 | 0.290 |
Why?
|
| Thrombosis | 3 | 2022 | 529 | 0.290 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 16 | 0.290 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 652 | 0.290 |
Why?
|
| Humans | 30 | 2025 | 132348 | 0.280 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 374 | 0.280 |
Why?
|
| Citric Acid | 2 | 2018 | 39 | 0.280 |
Why?
|
| Hepatitis | 1 | 2008 | 58 | 0.270 |
Why?
|
| Prognosis | 4 | 2024 | 5010 | 0.270 |
Why?
|
| Blood Group Incompatibility | 2 | 2018 | 27 | 0.270 |
Why?
|
| Adolescent | 10 | 2024 | 20553 | 0.270 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 140 | 0.260 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 66 | 0.260 |
Why?
|
| Risk Factors | 6 | 2024 | 10911 | 0.260 |
Why?
|
| Mice, Knockout | 5 | 2023 | 3873 | 0.260 |
Why?
|
| Heart | 2 | 2011 | 699 | 0.250 |
Why?
|
| Liver Diseases | 2 | 2022 | 387 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 6 | 2023 | 4767 | 0.250 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 697 | 0.240 |
Why?
|
| Length of Stay | 3 | 2024 | 1378 | 0.240 |
Why?
|
| Female | 18 | 2024 | 70795 | 0.230 |
Why?
|
| Heart Failure | 1 | 2018 | 2386 | 0.230 |
Why?
|
| Treatment Outcome | 8 | 2022 | 13017 | 0.220 |
Why?
|
| Critical Illness | 4 | 2021 | 617 | 0.220 |
Why?
|
| Ferritins | 2 | 2021 | 108 | 0.200 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 57 | 0.190 |
Why?
|
| Necrosis | 1 | 2022 | 210 | 0.180 |
Why?
|
| Gastroenterology | 1 | 2024 | 211 | 0.180 |
Why?
|
| Hemodiafiltration | 1 | 2021 | 18 | 0.180 |
Why?
|
| Intensive Care Units | 2 | 2018 | 524 | 0.180 |
Why?
|
| Fatty Acids | 2 | 2016 | 365 | 0.180 |
Why?
|
| Survival Rate | 2 | 2024 | 2187 | 0.170 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 67 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2023 | 324 | 0.170 |
Why?
|
| Animals | 9 | 2023 | 34995 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 170 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 149 | 0.160 |
Why?
|
| Gastroenteritis | 1 | 2023 | 366 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4695 | 0.160 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 194 | 0.150 |
Why?
|
| Bacteremia | 1 | 2023 | 428 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5405 | 0.150 |
Why?
|
| Serum Albumin, Human | 1 | 2018 | 8 | 0.150 |
Why?
|
| Cause of Death | 2 | 2018 | 503 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2018 | 4725 | 0.150 |
Why?
|
| Ventricular Function, Left | 2 | 2014 | 545 | 0.150 |
Why?
|
| Sepsis | 1 | 2023 | 518 | 0.150 |
Why?
|
| Hemofiltration | 1 | 2018 | 11 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 38 | 0.150 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 37 | 0.150 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 67 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 92 | 0.140 |
Why?
|
| Liver Failure | 1 | 2018 | 91 | 0.140 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 87 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2021 | 1570 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1297 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 278 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8568 | 0.120 |
Why?
|
| Echocardiography | 2 | 2019 | 1125 | 0.110 |
Why?
|
| Mice | 6 | 2023 | 18572 | 0.110 |
Why?
|
| Time Factors | 3 | 2017 | 6456 | 0.110 |
Why?
|
| Tissue Donors | 1 | 2018 | 508 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 667 | 0.110 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2013 | 17 | 0.110 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2014 | 78 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2014 | 252 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 196 | 0.100 |
Why?
|
| Catheterization | 1 | 2014 | 240 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3062 | 0.100 |
Why?
|
| Cardiovirus Infections | 1 | 2011 | 7 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 818 | 0.090 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2011 | 50 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 461 | 0.090 |
Why?
|
| Portal Vein | 2 | 2022 | 91 | 0.090 |
Why?
|
| Dicarbethoxydihydrocollidine | 1 | 2010 | 3 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 168 | 0.080 |
Why?
|
| Glycogen | 1 | 2010 | 54 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 51 | 0.080 |
Why?
|
| Myocarditis | 1 | 2011 | 130 | 0.080 |
Why?
|
| Recurrence | 1 | 2014 | 1458 | 0.080 |
Why?
|
| Amino Acids | 2 | 2023 | 672 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 213 | 0.080 |
Why?
|
| Gene Expression | 2 | 2013 | 1564 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 5150 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 308 | 0.080 |
Why?
|
| Fatigue | 1 | 2010 | 198 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3422 | 0.080 |
Why?
|
| Chemokine CXCL2 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 428 | 0.070 |
Why?
|
| Cholesterol, Dietary | 1 | 2008 | 48 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2008 | 52 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 55 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 119 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2011 | 781 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2011 | 988 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2008 | 296 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2008 | 212 | 0.060 |
Why?
|
| Organ Dysfunction Scores | 1 | 2025 | 50 | 0.060 |
Why?
|
| Asia | 1 | 2025 | 126 | 0.060 |
Why?
|
| Brain Edema | 1 | 2024 | 71 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 3391 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 3087 | 0.050 |
Why?
|
| India | 1 | 2024 | 240 | 0.050 |
Why?
|
| Receptors, Purinergic | 1 | 2023 | 14 | 0.050 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2023 | 17 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1443 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 1126 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 89 | 0.050 |
Why?
|
| Texas | 1 | 2011 | 3629 | 0.050 |
Why?
|
| Cytokines | 2 | 2023 | 1368 | 0.050 |
Why?
|
| Adenoviruses, Human | 1 | 2023 | 97 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1451 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 173 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 47 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 306 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2687 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 89 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2011 | 3710 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 656 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 342 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2021 | 111 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 407 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 101 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 121 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 101 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2023 | 795 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4545 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 6540 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 596 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 778 | 0.040 |
Why?
|
| Graft Survival | 1 | 2022 | 475 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1357 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 241 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 713 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11628 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1163 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 560 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 889 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 672 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 56 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 99 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 117 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 378 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1076 | 0.020 |
Why?
|
| Calcium | 1 | 2017 | 1083 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2228 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2013 | 241 | 0.020 |
Why?
|
| Encephalomyocarditis virus | 1 | 2011 | 8 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 764 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 31619 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9945 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 830 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 799 | 0.020 |
Why?
|
| Viral Load | 1 | 2011 | 410 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1085 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 544 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2931 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1292 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1723 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1904 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2453 | 0.020 |
Why?
|